Therefore, angiotensin-converting enzyme (ACE) inhibitors and angiotensin type 1 (AT1) receptor blockers are widely used in diabetic nephropathy at present, which partly interfere with TGF-β expression mediated by ANG II (Wolf, 2006). The gene discussed is AGT; the disease is diabetic kidney disease.